期刊文献+

吉西他滨诱导人NK/T细胞淋巴瘤细胞株SNK-6凋亡的机制 被引量:1

Apoptosis of NK/T Lymphoma Cell Line SNK-6 Induced by Gemcitabine
下载PDF
导出
摘要 目的探讨吉西他滨诱导人NK/T细胞淋巴瘤细胞株SNK-6产生凋亡的机制。方法应用MTT法、DNA电泳技术及流式细胞术观察吉西他滨诱导人SNK-6细胞凋亡情况,应用基因芯片技术分析加药前后凋亡相关基因的表达差异。结果吉西他滨作用后,MTT结果显示细胞生长抑制率随药物浓度的增加而逐渐增大;DNA断裂电泳可见典型的梯形DNA条带,随吉西他滨作用浓度的增加而逐渐增强;流式细胞术分析,2μg/ml吉西他滨作用SNK-6细胞4、8、24、48h后,凋亡细胞比例分别为2.1%、8.3%、23.9%、30.9%;吉西他滨作用48h后,在88条有关凋亡的目的基因中共有17条基因表达发生大于3倍的显著变化,其中表达上调基因4条,下调基因13条。结论吉西他滨可以诱导人NK/T细胞淋巴瘤细胞产生凋亡,呈时间和剂量依赖性;吉西他滨可使SNK-6细胞中多个凋亡相关基因的表达发生改变,初步揭示了其诱导淋巴瘤细胞凋亡的作用机制。 Objective To investigate the apoptosis induced by gemcitabine in human NK/T lymphoma cell line SNK-6.Methods MTT,DNA fragmentation and flow cytometry(FCM) analysis were used to detect apoptosis of SNK-6 cells induced by gemcitabine.A human apoptosis microarray containing 88 cDNA fragments was used to detect apoptosis related genes expression difference.Results Gemcitabine could inhibit the growth rate of SNK-6 cells after 48h treatment in a concentration-dependent manner.DNA ladder was observed on DNA electrophoresis and its intensity increased with the increased concentration of gemcitabine.FCM assay revealed that apoptosis cells respectively accounted for 2.1%,8.3%,23.9%,30.9% of total cells respectively after exposure to 2 μg/ml gemcitabine for 4,8,24,48 h.cDNA microarray analysis identified 4 up-regulated and 13 down-regulated genes with more than three-fold change in the first 48h as a consequence of treatment.Conclusion Gemcitabine can induce apoptosis of human NK/T lymphoma cell line SNK-6 cells in a time-dependent and concentration-dependent manner and alter the expression profile of apoptosis-related genes in this cell line,which provides valuable insight into the mechanism of the gemcitabine-induced apoptosis.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2013年第8期733-736,共4页 Cancer Research on Prevention and Treatment
基金 国家自然科学基金资助项目(81172118)
关键词 淋巴瘤 吉西他滨 细胞凋亡 Lymphoma Gemcitabine Apoptosis
  • 相关文献

参考文献14

  • 1Borson R, Harker G, Reeves J ,et al. Phase II study of gemcit- abine and bevacizumab as first-line treatment in taxane-pre treated, HER2-negative, locally recurrent or metastatic breast cancer [J]. Clinical Breast Cancer,2012,12(5) :322-30.
  • 2Dudek AZ,Kumar P, H Thaw SS,et al. Phase II Study of Bi- weekly Carboplatin, Gemcitabine, and Bevacizumab as First line Treatment in Patients with Stage IIIB/IV NSCLC[J]. Am J Clin Oneol,2012. [Epub ahead of print].
  • 3Goldstein D, Spry N, Cummins MM, et al. The GOFURTGO Study:AGITG phase II study of fixed dose rate gemeitabine- oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer [J]. BrJ Cancer,2012,106(1) :61-9.
  • 4Ahn IlK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/ T-cell lymphoma[J]. Invest New Drugs,2013,31 (2) :469-72.
  • 5Huang P, Plunkett W. Induction of apoptosis by gemcitabine [J]. Semin Oncol, 1995,22(4 Suppl 11 ) : 19-25.
  • 6Zheng T, Wang J, Chen X, et al. Disruption of p73-MDM2 binding synergizes with gemeitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation[J]. Tumour Biol, 2010,31 (4) : 287-95 .
  • 7Kawanami T, Takiguchi S, Ikeda N, et al. A humanized anti- IGF-1R monoelonal antibody (R1507) and/or metformin en- hance gemeitabine-induced apoptosis in pancreatic cancer cells [J]. Oncol Rep,2012,27(3) :867-72.
  • 8Kim MK, Jeon YK, Woo JK, et al. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-in- duced apoptosis by suppressing NF-κB activity and down-regu- lating Bfl-1[J]. Mol Cancer,2011,10:98.
  • 9邵军,黄韬,樊海宁.吉西他滨诱导乳腺癌MCF-7细胞凋亡[J].华中科技大学学报(医学版),2005,34(2):217-219. 被引量:2
  • 10王亚帝,哈敏文,安煜致,王月,成健,刘维.单药吉西他滨治疗老年晚期非小细胞肺癌疗效观察[J].肿瘤防治研究,2011,38(6):698-700. 被引量:6

二级参考文献37

  • 1曹炜,牛建昭.细胞凋亡(Apoptosis)研究概况[J].解剖学报,1995,26(4):443-445. 被引量:19
  • 2赵永同,朱峰.凋亡的分子机理[J].生命科学,1996,8(2):19-23. 被引量:24
  • 3刘青.调节细胞凋亡的信号传递机制[J].国外医学:免疫学分册,1995,5:270-270.
  • 4GREENDR.Apoptoticpathways : paperwrapsstonebluntsscissors [J ]. Cell ,2005,102(4) : 1-5.
  • 5GREENDR,Reed J C.Mitochondrionandapoptosis [J].Science, 2007,281 (28) : 1309.
  • 6BRENNERC,KROEMERG.The mitoehondrion:decisive for cell death control? Signaling pathway inapoptosis [M].Hawood academic publishers, 2002,13 (3) : 207.
  • 7REEDJC, MATASUYAMAS, QUINNL,et al.Apoptosisand the laws of thermodynamics[J].Nature Cell Biol,2005,101 (4) :398.
  • 8DUC,FANGM,LIL,et al.Smac,amitoehondrial protein that promotescy tochromec 2 dependent caspase activation by eliminating IAP inhibition [ J ].Cell, 2005,102 ( 12 ) : 33.
  • 9MARTINOUSJC, DESAGHERS, ANTONSSONB.Cytochrome crelease from mitochondria:allornothing [J].Nature cell biology, 2000,2(9) :41.
  • 10LIK,LIY, SHELTONJM,et al.Cytochromec deficiency cause sembry oniele thality and attenuates stress inducedapoptosis[J].Cell, 2004,101 (4) :398.

共引文献10

同被引文献23

  • 1姚波,李晔雄,宋永文,金晶,刘跃平,王维虎,王淑莲,孙耘田,余子豪,刘新帆.原发鼻腔非霍奇金淋巴瘤的治疗选择和疗效[J].中华肿瘤杂志,2006,28(1):58-61. 被引量:14
  • 2HMIDI M, KETTANI M, ELBOUKHARI A, et al. Sinonasal NK/T-cell lymphoma [ J ] . Euro Ann Otorhinolaryngol Head Neck Dis, 2012, 10(6): 204-207.
  • 3JACCARD A, HERMINE O. Extranodal natural killer/T-cell lymphoma: advances in the management [ J ] . Curr Opin Oncol, 2011, 23(6): 429-435.
  • 4CHEN Z S, TIWARI A K. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases [ J ] . FEBS, 2011, 9 (18): 3226-3245.
  • 5YANG A K, ZHOU Z W, WET M Q, et al. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases [ J ] . Curt Top Med Chem, 2010, 10(17): 1732-1756.
  • 6WAKAMATSU T, NAKAHASHI Y, HACHIMINE D, et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of muhidrug resistance-associated proteins [ J ] . Int J Oncol, 2007, 31(6): 1465-1472.
  • 7KRUH G D, BELINSKY M G.The MRP family of drug efflux pumps [ J ] . Oncogene, 2003, 22(1): 7537-7552.
  • 8LIU Y H, DI Y M, ZHOU Z W, et al. Muhidrug resistance- associated proteins and implications in drug development [ J ] . Clin Exp Pharmacol Physiol, 2010, 37(1): 115-120.
  • 9KONIG J, HARTEL M, NIES A T, et al. Expression and localization of human muhidrug resistance protein (ABCC) family members in pancreatic carcinoma [ J ] . Cancer, 2005, 11(8): 359-367.
  • 10YAN J, ZHANG M, CHEN Q, et al. Expression of AEG-I in human T-cell lymphoma enhances the risk of progression [ J ] . Oncol Rep, 2012, 28(6): 2107-2114.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部